nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—HTR1B—attention deficit hyperactivity disorder	0.849	1	CbGaD
Frovatriptan—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00153	0.0872	CbGeAlD
Frovatriptan—HTR1D—forebrain—attention deficit hyperactivity disorder	0.00148	0.0844	CbGeAlD
Frovatriptan—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00129	0.0737	CbGeAlD
Frovatriptan—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.00125	0.0714	CbGeAlD
Frovatriptan—HTR1A—forebrain—attention deficit hyperactivity disorder	0.00123	0.0703	CbGeAlD
Frovatriptan—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.00104	0.0595	CbGeAlD
Frovatriptan—HTR1B—midbrain—attention deficit hyperactivity disorder	0.00101	0.0576	CbGeAlD
Frovatriptan—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000978	0.0557	CbGeAlD
Frovatriptan—HTR1B—nervous system—attention deficit hyperactivity disorder	0.00083	0.0473	CbGeAlD
Frovatriptan—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000815	0.0464	CbGeAlD
Frovatriptan—HTR1B—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.000814	0.00608	CbGpPWpGaD
Frovatriptan—HTR1A—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.000812	0.00607	CbGpPWpGaD
Frovatriptan—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000804	0.0458	CbGeAlD
Frovatriptan—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.0008	0.0456	CbGeAlD
Frovatriptan—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000774	0.0441	CbGeAlD
Frovatriptan—HTR1D—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000763	0.0057	CbGpPWpGaD
Frovatriptan—HTR1B—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000747	0.00558	CbGpPWpGaD
Frovatriptan—HTR1A—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000677	0.00506	CbGpPWpGaD
Frovatriptan—HTR1A—nervous system—attention deficit hyperactivity disorder	0.00067	0.0382	CbGeAlD
Frovatriptan—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000645	0.0368	CbGeAlD
Frovatriptan—HTR1B—brain—attention deficit hyperactivity disorder	0.000635	0.0362	CbGeAlD
Frovatriptan—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000631	0.0359	CbGeAlD
Frovatriptan—HTR1A—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.00062	0.00463	CbGpPWpGaD
Frovatriptan—HTR1D—brain—attention deficit hyperactivity disorder	0.000615	0.035	CbGeAlD
Frovatriptan—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000589	0.0044	CbGpPWpGaD
Frovatriptan—HTR1A—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000569	0.00425	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000557	0.00417	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000546	0.00408	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000517	0.00387	CbGpPWpGaD
Frovatriptan—HTR1A—brain—attention deficit hyperactivity disorder	0.000512	0.0292	CbGeAlD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000507	0.00379	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000506	0.00378	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000503	0.00376	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000496	0.00371	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000493	0.00368	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000443	0.00331	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000434	0.00324	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000434	0.00324	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000425	0.00318	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000416	0.00311	CbGpPWpGaD
Frovatriptan—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000399	0.00298	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000398	0.00298	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000386	0.00288	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000378	0.00283	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000378	0.00282	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000375	0.0028	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000371	0.00277	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000351	0.00262	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000344	0.00257	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000342	0.00256	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000337	0.00252	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000331	0.00247	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000331	0.00247	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000331	0.00247	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00033	0.00247	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000324	0.00242	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000324	0.00242	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000318	0.00238	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.000318	0.00238	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000307	0.00229	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000301	0.00225	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000298	0.00223	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000295	0.0022	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000293	0.00219	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000292	0.00218	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000289	0.00216	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000287	0.00214	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000285	0.00213	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000284	0.00212	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000283	0.00212	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000282	0.00211	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000279	0.00209	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000278	0.00208	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000276	0.00207	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000272	0.00203	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000271	0.00202	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000269	0.00201	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000268	0.00201	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000266	0.00199	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000264	0.00197	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000263	0.00197	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000263	0.00196	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000262	0.00196	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000258	0.00193	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000253	0.00189	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000252	0.00188	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00025	0.00187	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000247	0.00184	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000247	0.00184	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000245	0.00183	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000245	0.00183	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00024	0.00179	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000239	0.00179	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000237	0.00177	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000233	0.00174	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000232	0.00173	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000231	0.00173	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00023	0.00172	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000229	0.00171	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000229	0.00171	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000228	0.0017	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000225	0.00168	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000224	0.00168	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000224	0.00168	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000222	0.00166	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000218	0.00163	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000216	0.00161	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000214	0.0016	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000213	0.00159	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000212	0.00158	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00021	0.00157	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000206	0.00154	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000203	0.00151	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000201	0.0015	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.0002	0.0015	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0002	0.0015	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000196	0.00147	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000195	0.00146	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000193	0.00144	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000191	0.00143	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000187	0.0014	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000187	0.0014	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000186	0.00139	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000186	0.00139	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000183	0.00137	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000182	0.00136	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000182	0.00136	CbGpPWpGaD
Frovatriptan—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000181	0.00135	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00018	0.00135	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000177	0.00132	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000177	0.00132	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000177	0.00132	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000175	0.00131	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000175	0.00131	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.0013	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000174	0.0013	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000173	0.00129	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000171	0.00128	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000171	0.00128	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000171	0.00128	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000171	0.00128	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00017	0.00127	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00017	0.00127	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000166	0.00124	CbGpPWpGaD
Frovatriptan—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000166	0.00124	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000163	0.00122	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00016	0.00119	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00016	0.00119	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000153	0.00114	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00015	0.00112	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000149	0.00112	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000149	0.00112	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000147	0.0011	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000142	0.00106	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000139	0.00104	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000139	0.00104	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000135	0.00101	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000132	0.000988	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000131	0.000976	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000131	0.000976	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00013	0.000968	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000129	0.000965	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000127	0.000948	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000127	0.000946	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000122	0.000909	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000119	0.000891	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000119	0.000891	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000119	0.00089	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000118	0.000879	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000117	0.000871	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000115	0.000861	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000114	0.000854	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000114	0.00085	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000113	0.000846	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000112	0.000836	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000112	0.000836	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000105	0.000786	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000103	0.000773	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000103	0.00077	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000103	0.000768	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000102	0.000765	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000102	0.000762	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.0001	0.000749	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.0001	0.000749	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.0001	0.000749	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	9.98e-05	0.000746	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	9.89e-05	0.000739	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	9.83e-05	0.000735	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	9.81e-05	0.000733	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	9.81e-05	0.000733	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	9.69e-05	0.000724	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	9.68e-05	0.000724	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	9.66e-05	0.000722	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	9.62e-05	0.000719	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	9.61e-05	0.000718	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	9.56e-05	0.000714	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	9.55e-05	0.000714	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	9.36e-05	0.000699	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	9.26e-05	0.000692	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	9.22e-05	0.000689	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	9.1e-05	0.00068	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	9.06e-05	0.000677	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	9.02e-05	0.000674	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.98e-05	0.000671	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	8.91e-05	0.000666	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	8.88e-05	0.000664	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.8e-05	0.000657	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	8.77e-05	0.000656	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	8.52e-05	0.000637	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	8.44e-05	0.000631	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.37e-05	0.000625	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.2e-05	0.000612	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	7.85e-05	0.000587	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	7.67e-05	0.000573	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	7.63e-05	0.00057	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	7.6e-05	0.000568	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	7.48e-05	0.000559	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	7.47e-05	0.000558	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	7.38e-05	0.000552	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	7.33e-05	0.000548	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	7.13e-05	0.000533	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.95e-05	0.000519	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	6.9e-05	0.000516	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	6.88e-05	0.000514	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.8e-05	0.000508	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	6.79e-05	0.000507	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	6.7e-05	0.000501	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.46e-05	0.000482	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.32e-05	0.000472	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.24e-05	0.000467	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.07e-05	0.000454	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.86e-05	0.000438	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.74e-05	0.000429	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.65e-05	0.000422	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.53e-05	0.000413	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.47e-05	0.000409	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.37e-05	0.000402	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.35e-05	0.0004	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.31e-05	0.000397	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.26e-05	0.000393	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.2e-05	0.000388	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.18e-05	0.000387	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.94e-05	0.000369	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.84e-05	0.000362	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.82e-05	0.00036	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.53e-05	0.000338	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.37e-05	0.000327	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.21e-05	0.000315	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.08e-05	0.000305	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.01e-05	0.0003	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.96e-05	0.000296	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.96e-05	0.000296	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.69e-05	0.000276	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.46e-05	0.000259	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.39e-05	0.000253	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	2.73e-05	0.000204	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.73e-05	0.000204	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	2.69e-05	0.000201	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.58e-05	0.000193	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.5e-05	0.000187	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.18e-05	0.000163	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.08e-05	0.000155	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.83e-05	0.000137	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.8e-05	0.000134	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	1.66e-05	0.000124	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	1.64e-05	0.000123	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.59e-05	0.000119	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.37e-05	0.000102	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	7.1e-06	5.31e-05	CbGpPWpGaD
